Drugs Made In America Acquisition Corp. (DMAAR) Preferred Stock Liabilities (2025 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Preferred Stock Liabilities for 2 consecutive years, with $145.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Preferred Stock Liabilities fell 38.27% year-over-year to $145.2 million; the trailing twelve-month figure through Jun 2026 stood at $145.2 million (down 38.27% YoY), and the FY2025 full-year result was $239.9 million, changed N/A from the prior year.
• Preferred Stock Liabilities fell to $145.2 million in Q2 2026 per DMAAR's latest filing, from $239.9 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $239.9 million in Q4 2025 and bottomed at $145.2 million in Q2 2026.